您当前的位置: 首页 > 资源详情

Science Daily,9月1日,Double vaccination halves risk of long COVID, study finds

编译者:YUTING发布时间:Sep 11, 2021点击量:107 来源栏目:最新研究

Researchers at King's College London analysed data from participants logging their symptoms, tests and vaccines on the UK ZOE COVID Symptom Study app between 8th December 2020 and 4 July 2021, including 1,240,009 (first dose) and 971,504 (second dose) vaccinated UK adults. The research team assessed a range of factors, including age, frailty and areas of deprivation and compared that with post-vaccination infection.

The study, published today in The Lancet Infectious Diseases, found that in the unlikely event of catching COVID-19 after being double vaccinated, the risk of Long COVID was reduced by almost half. There were also fewer hospitalisations (73% less likely) and lower burden of acute symptoms (31% less likely) among those fully vaccinated. The nature of the most common symptoms were similar to unvaccinated adults -- e.g. anosmia,(loss of smell) cough, fever, headaches, and fatigue. All these symptoms were milder and less frequently reported by people who were vaccinated, and they were half as likely to get multiple symptoms in the first week of illness. Sneezing was the only symptom which was more commonly reported in vaccinated people with COVID-19.

However, people living in most deprived areas were at greater risk of infection after a single vaccination. While age on its own was not a risk factor, individuals who had health conditions that limited their independence -- such as frailty -- were up to two times more likely to contract COVID-19 infection after vaccination, and of getting sick.

The findings demonstrate the need to target at-risk groups. Frail adults have already been shown to be disproportionately affected by COVID-19. The research team suggests strategies such as a timely booster programme, targeted infection control measures and more research into the immune response to vaccination in this group could help address the issue.

Lead researcher Dr Claire Steves from King's College London said: "In terms of the burden of Long COVID, it's good news that our research has found that having a double vaccination significantly reduces the risk of both catching the virus and if you do, developing long standing symptoms. However, among our frail, older adults and those living in deprived areas the risk is still significant and they should be urgently prioritised for second and booster vaccinations."

Professor Tim Spector from King's College London and Lead investigator of ZOE COVID Study comments: "Vaccinations are massively reducing the chances of people getting Long COVID in two ways. Firstly, by reducing the risk of any symptoms by 8 to 10 fold and then by halving the chances of any infection turning into Long COVID, if it does happen. Whatever the duration of symptoms we are seeing that infections after two vaccinations are also much milder, so vaccines are really changing the disease and for the better. We are encouraging people to get their 2nd jab as soon as they can."

Health and Social Care Secretary, Sajid Javid said: "COVID-19 vaccines have saved more than 105,000 lives and prevented over 24 million infections in England alone. This research is encouraging, suggesting vaccines are not only preventing deaths but could also help prevent some of the longer lasting symptoms.

"We have invested £50 million in research to better understand the lasting effects of COVID and over 80 long COVID assessment services have opened across England as part of a £100 million expansion of care for those suffering the effects.

"It is clear vaccines are building a wall of defence against the virus and are the best way to protect people from serious illness. I encourage everyone who is eligible to come forward for both their jabs as quickly as possible."https://www.sciencedaily.com/releases/2021/09/210901191407.htm

提供服务:导出本资源
  1. 1 Nature,11月10日,Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility
  2. 2 11月10日_研究人员分析宿主基因对COVID-19严重程度和易感性的影响
  3. 3 11月11日_新冠药物Remestemcel-L二期临床的中期分析结果积极
  4. 4 11月11日_CDC呼吁制定通用口罩规定以减少新冠传播
  5. 5 SSRN,2月20日,Dynamics of the Latest 2019 Novel Coronavirus Disease Epidemic in China: A Descriptive Study
  6. 6 SSRN,2月20日,Mental Health Problems and Social Media Exposure During COVID-19 Outbreak
  7. 7 SSRN,2月20日,Evaluating Incidence and Impact Estimates of the Coronavirus Outbreak from Official and Non-Official Chinese Data Sources
  8. 8 SSRN,2月20日,Clinical Characteristics and Treatment of Patients Infected with COVID-19 in Shishou, China
  9. 9 Nature,11月10日,Mobility network models of COVID-19 explain inequities and inform reopening
  10. 10 1月27日_Nature报道中国新型冠状病毒最新研究进展:病毒传播速度有多快?
  1. 1 10月11日_SARS-CoV-2变体对mRNA疫苗诱导的免疫反应的影响
  2. 2 10月11日_SARS-CoV-2变体对mRNA疫苗诱导的免疫反应的影响
  3. 3 Medicalxpress,10月11日,Vaccines prevent severe COVID, even from Delta: study
  4. 4 10月11日_疫苗接种可预防严重COVID-19
  5. 5 PR Newswire,10月11日,INOVIO Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization
  6. 6 10月11日_INOVIO扩展其COVID-19疫苗INO-4800的3期研究
  7. 7 ACCESSWIRE,10月11日,NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity
  8. 8 10月11日_NV-CoV-2具有广谱的抗冠状病毒活性
  9. 9 CIDRAP,10月11日,Merck applies for approval of first COVID-19 antiviral pill
  10. 10 10月11日_默沙东向FDA申请首款COVID-19抗病毒药丸的EUA

版权所有@2017中国科学院文献情报中心

制作维护:中国科学院文献情报中心信息系统部地址:北京中关村北四环西路33号邮政编号:100190